[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients.  Am J Gastroenterol. 2000;95(11):3118-312211095327PubMedGoogle Scholar
2.
Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service.  Ann Pharmacother. 2006;40(7-8):1261-126616804095PubMedGoogle ScholarCrossref
3.
Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients.  Am J Gastroenterol. 2006;101(10):2200-220516952283PubMedGoogle ScholarCrossref
4.
Parente F, Cucino C, Gallus S,  et al.  Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey.  Aliment Pharmacol Ther. 2003;17(12):1503-150612823152PubMedGoogle ScholarCrossref
5.
Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, Pazzi P. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice.  Dig Dis Sci. 2005;50(12):2307-231116416179PubMedGoogle ScholarCrossref
6.
Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence.  J Hosp Med. 2007;2(2):86-9217427249PubMedGoogle ScholarCrossref
7.
Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units.  Am J Health Syst Pharm. 2007;64(13):1396-140017592004PubMedGoogle ScholarCrossref
8.
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.  Arch Intern Med. 2007;167(9):950-95517502537PubMedGoogle ScholarCrossref
9.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.  JAMA. 2004;292(16):1955-196015507580PubMedGoogle ScholarCrossref
10.
Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia.  Ann Intern Med. 2008;149(6):391-39818794558PubMedGoogle ScholarCrossref
11.
American Thoracic Society; Infectious Diseases Society of America.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;171(4):388-41615699079PubMedGoogle ScholarCrossref
12.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;40(5):373-3833558716PubMedGoogle ScholarCrossref
13.
Quan H, Sundararajan V, Halfon P,  et al.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.  Med Care. 2005;43(11):1130-113916224307PubMedGoogle ScholarCrossref
14.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data.  Med Care. 1998;36(1):8-279431328PubMedGoogle ScholarCrossref
15.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects.  Biometrika. 1983;70(1):41-55Google ScholarCrossref
16.
Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS (Users Group International Conference). http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed April 29, 2009
17.
Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.  CMAJ. 2004;171(1):33-3815238493PubMedGoogle ScholarCrossref
18.
Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile–associated disease.  JAMA. 2005;294(23):2989-299516414946PubMedGoogle ScholarCrossref
19.
Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile–associated disease: a population-based study.  Clin Infect Dis. 2006;43(10):1272-127617051491PubMedGoogle ScholarCrossref
20.
Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile–associated diarrhea in hospitalized patients.  Am J Gastroenterol. 2008;103(9):2308-231318702653PubMedGoogle ScholarCrossref
21.
Prod’hom G, Leuenberger P, Koerfer J,  et al.  Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer: a randomized controlled trial.  Ann Intern Med. 1994;120(8):653-6628135449PubMedGoogle ScholarCrossref
22.
Cook DJ, Reeve BK, Guyatt GH,  et al.  Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses.  JAMA. 1996;275(4):308-3148544272PubMedGoogle ScholarCrossref
23.
Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials.  BMJ. 2000;321(7269):1103-110611061729PubMedGoogle ScholarCrossref
24.
Kantorova I, Svoboda P, Scheer P,  et al.  Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.  Hepatogastroenterology. 2004;51(57):757-76115143910PubMedGoogle Scholar
25.
Apte NM, Karnad DR, Medhekar TP, Tilve GH, Morye S, Bhave GG. Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: a randomized, controlled trial.  Crit Care Med. 1992;20(5):590-5931572183PubMedGoogle ScholarCrossref
26.
Driks MR, Craven DE, Celli BR,  et al.  Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers: the role of gastric colonization.  N Engl J Med. 1987;317(22):1376-13822891032PubMedGoogle ScholarCrossref
27.
Mallow S, Rebuck JA, Osler T, Ahern J, Healey  MA, Rogers FB. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?  Curr Surg. 2004;61(5):452-45815475094PubMedGoogle ScholarCrossref
28.
 ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis: ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998.  Am J Health Syst Pharm. 1999;56(4):347-37910690219PubMedGoogle Scholar
29.
du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway.  Lancet. 1982;1(8266):242-2456120273PubMedGoogle ScholarCrossref
30.
Donowitz LG, Page MC, Mileur BL, Guenthner SH. Alteration of normal gastric flora in critical care patients receiving antacid and cimetidine therapy.  Infect Control. 1986;7(1):23-263633241PubMedGoogle Scholar
31.
Garvey BM, McCambley JA, Tuxen DV. Effects of gastric alkalization on bacterial colonization in critically ill patients.  Crit Care Med. 1989;17(3):211-2162920561PubMedGoogle ScholarCrossref
32.
Hartmann M, Theiss U, Huber R,  et al.  Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.  Aliment Pharmacol Ther. 1996;10(3):359-3668791964PubMedGoogle ScholarCrossref
33.
Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity.  Gen Pharmacol. 1995;26(6):1413-14187590140PubMedGoogle ScholarCrossref
34.
Scaringi L, Cornacchione P, Fettucciari K,  et al.  Activity inhibition of cytolytic lymphocytes by omeprazole.  Scand J Immunol. 1996;44(3):204-2148795713PubMedGoogle ScholarCrossref
35.
Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function.  Immunopharmacol Immunotoxicol. 1999;21(2):357-37710319286PubMedGoogle ScholarCrossref
36.
Mikawa K, Akamatsu H, Nishina K,  et al.  The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions.  Anesth Analg. 1999;89(1):218-22410389808PubMedGoogle Scholar
37.
Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity.  Crit Care Med. 2002;30(5):1118-112212006811PubMedGoogle ScholarCrossref
38.
 HCUP facts and figures, 2006: statistics on hospital-based care in the United States. Healthcare Cost and Utilization Project (HCUP). http://www.hcup-us.ahrq.gov/reports/factsandfigures/facts_figures_2006.jsp. Accessed November 8, 2008
39.
Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care–associated pneumonia: results from a large US database of culture-positive pneumonia.  Chest. 2005;128(6):3854-386216354854PubMedGoogle ScholarCrossref
40.
Venditti M, Falcone M, Corrao S, Licata G, Serra P.Study Group of the Italian Society of Internal Medicine.  Outcomes of patients hospitalized with community-acquired, health care–associated, and hospital-acquired pneumonia.  Ann Intern Med. 2009;150(1):19-2619124816PubMedGoogle ScholarCrossref
41.
Adams K, ed, Corrigan JM, ed.Committee on Identifying Priority Areas for Quality Improvement.  Priority Areas for National Action: Transforming Health Care Quality. Rockville, MD: Agency for Healthcare Research and Quality; 2003
42.
Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings.  J Hosp Med. 2006;1(1):13-2017219466PubMedGoogle ScholarCrossref
Original Contribution
May 27, 2009

Acid-Suppressive Medication Use and the Risk for Hospital-Acquired Pneumonia

Author Affiliations

Author Affiliations: Divisions of General Medicine and Primary Care (Drs Herzig, Ngo, and Marcantonio), Pulmonary and Critical Care (Dr Howell), and Gerontology (Dr Marcantonio), Beth Israel Deaconess Medical Center, Boston, Massachusetts; and Harvard Medical School, Boston (Drs Herzig, Howell, Ngo, and Marcantonio).

JAMA. 2009;301(20):2120-2128. doi:10.1001/jama.2009.722
Abstract

Context The use of acid-suppressive medication has been steadily increasing, particularly in the inpatient setting, despite lack of an accepted indication in the majority of these patients.

Objective To examine the association between acid-suppressive medication and hospital-acquired pneumonia.

Design, Setting, and Patients Prospective pharmacoepidemiologic cohort study. All patients who were admitted to a large, urban, academic medical center in Boston, Massachusetts, from January 2004 through December 2007; at least 18 years of age; and hospitalized for 3 or more days were eligible for inclusion. Admissions with time spent in the intensive care unit were excluded. Acid-suppressive medication use was defined as any order for a proton-pump inhibitor or histamine2 receptor antagonist. Traditional and propensity-matched multivariable logistic regression were used to control for confounders.

Main Outcome Measure Incidence of hospital-acquired pneumonia, defined via codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), in patients exposed and unexposed to acid-suppressive medication.

Results The final cohort comprised 63 878 admissions. Acid-suppressive medication was ordered in 52% of admissions and hospital-acquired pneumonia occurred in 2219 admissions (3.5%). The unadjusted incidence of hospital-acquired pneumonia was higher in the group exposed to acid-suppressive medication than in the unexposed group (4.9% vs 2.0%; odds ratio [OR], 2.6; 95% confidence interval [CI], 2.3-2.8). Using multivariable logistic regression, the adjusted OR of hospital-acquired pneumonia in the group exposed to acid-suppressive medication was 1.3 (95% CI, 1.1-1.4). The matched propensity-score analyses yielded identical results. The association was significant for proton-pump inhibitors (OR, 1.3; 95% CI, 1.1-1.4) but not for histamine2 receptor antagonists (OR, 1.2; 95% CI, 0.98-1.4).

Conclusions In this large, hospital-based pharmacoepidemiologic cohort, acid-suppressive medication use was associated with 30% increased odds of hospital-acquired pneumonia. In subset analyses, statistically significant risk was demonstrated only for proton-pump inhibitor use.

×